<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45207">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01870726</url>
  </required_header>
  <id_info>
    <org_study_id>CINC280X2204</org_study_id>
    <nct_id>NCT01870726</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma</brief_title>
  <official_title>A Phase Ib/II, Multi-center, Open-label Study of Single-agent INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Germany: German Institute of Medical Documentation and Information</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the safety and the dose of the combination of INC280 and buparlisib
      (BKM120), as well as the anti-tumor activity of the combination, in patients with recurrent
      glioblastoma  with PTEN mutations, homozygous deletion of PTEN or PTEN negative by IHC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part is to
      estimate the MTD and/or to identify the recommended phase II dose (RP2D) for the combination
      of INC280 and buparlisib, followed by the phase II part to assess the clinical efficacy and
      to further assess the safety of the combination. A maximum of 10 patients, who have received
      bevacizumab treatment before entering the study, will be enrolled in the phase II part. In
      addition, a surgical arm will start concurrently with the phase II part, to determine the
      PK/PD profile of the study drug combination in patients undergoing tumor resection for
      recurrent glioblastoma after 7 to 10-days treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Phase II: Progression free survival rate (PFSR)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Estimate anti-tumor activity of INC280 in combiation with buparlisib in patients with recurrent glioblastoma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Incidence of dose limiting toxicities</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Estimate the Maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of INC280 in combination with buparlisib in patients with recurrent glioblastoma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical arm: Concentrations of INC280 and buparlisib in tumor.</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Estimate the concentrations of INC280 and buparlisib in tumor tissue.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type, frequency, and severity of adverse events and serious adverse events.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To characterize the safety of INC280 in combination with buparlisib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability: dose interruptions, reductions and dose intensity.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To characterize the tolerability of INC280 in combination with buparlisib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of INC280 in combination with buparlisib.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Plasma concentration of INC280 and buparlisib, and PK parameters, including but not limited to Cmax, Tmax, AUCtau, and T1/2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Further assess the anti-tumor activity of INC280 in combination with buparlisib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of INC280 and buparlisib in cerebrospinal fluid (if available).</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To investigate drug level of INC280 and buparlisib in cerebrospinal fluid (if available).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Further assess the anti-tumor activity of INC280 in combination with buparlisib.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Deletion of PTEN or PTEN Negative by IHC, INC280, BKM120, Buparlisib; Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Phase Ib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To estimate the safe dose of the combination INC280 and buparlisib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To estimate anti-tumor efficaty of the combination INC280 and buparlisib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INC280</intervention_name>
    <description>INC280 will be given at the starting dose of 200mg twice daily.</description>
    <arm_group_label>Phase Ib</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buparlisib</intervention_name>
    <description>Buparlisib will be given at the starting dose of 50mg once daily.</description>
    <arm_group_label>Phase Ib</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>BKM120</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age.

          -  Histologically confirmed diagnosis of glioblastoma after initial tumor resection with
             radiographic evidence of recurrent tumor per RANO criteria.

          -  Documented evidence of PTEN mutations, homozygous deletion of PTEN or PTEN negative
             by IHC confirmed by local or central assessment

          -  Must have received the following treatment for glioblastoma:

               -  Prior adjuvant treatment with radiotherapy and temozolomide;

               -  A maximum of two prior chemotherapy regimens (including bevacizumab or other
                  direct VEFG/VEGFR inhibitors)  for recurrent disease are permitted.

          -  Representative archival or newly obtained tumor sample from glioblastoma
             (formalin-fixed paraffine embedded tissue) must be available.

          -  ECOG performance status ≥ 2.

          -  Able to swallow and retain oral medication.

          -  Patients in the surgical arm only: patients with recurrent glioblastoma must be
             eligible for surgical resection as deemed by the site Investigator.

        Exclusion Criteria:

          -  Prior or current treatment with a c-MET inhibitor or HGF-targeting therapy

          -  Prior treatment with a PI3K and/or mTOR inhibitors for glioblastoma

          -  Received radiation (including therapeutic radioisotopes such as strontium 89)
             therapy ≤ 4 weeks prior to the first dose of study treatment and have not recovered
             from side effects of such therapy (≤ Grade 1) prior to the first dose of study
             treatment, except for alopecia.

          -  Currently being treated with Enzyme Inducing Anti-Epileptic Drug (EIAED). If
             previously on an EIAED, the patient must be off of it for at least 2 weeks prior to
             study treatment.

          -  Currently receiving warfarin or other coumadin-derived anticoagulants for treatment,
             prophylaxis or otherwise.

          -  Currently receiving increasing or chronic treatment ( &gt; 5 days) with corticosteroids
             or another immunosuppressive agent.

          -  History of acute or chronic pancreatitis or any risk factors that may increase the
             risk of pancreatitis.

          -  Active cardiac disease or a history of cardiac dysfunction.

          -  Impairment of gastrointestinal (GI) function or GI disease that might significantly
             alter the absorption of study drug

          -  Medically documented history of or active major depressive episode, bipolar disorder
             (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal
             attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or
             others), or patients with active severe personality disorders (defined according to
             DSM- IV).

          -  Anxiety ≥ CTCAE grade 3

          -  Any of the following baseline laboratory values:

               -  Hemoglobin &lt; 9 g/dL

               -  Platelet count  &lt; 75 x 109/L

               -  Absolute neutrophil count (ANC) &lt; 1.0 x 109/L

               -  INR &gt; 1.5

               -  Serum lipase &gt; normal limits for the institution

               -  Asymptomatic serum amylase &gt; grade 2

               -  Potassium, magnesium, and calcium (corrected for albumin) &gt; normal limits for
                  the institution

               -  Total bilirubin ≥2 x upper limit of normal (ULN)

               -  Serum creatinine &gt;1.5 x ULN or creatinine clearance ≤ 45 mL/min

               -  Alanine aminotransferase (AST) or aspartate aminotransferase (ALT) &gt; normal
                  range (or &lt; 3.0 x ULN if liver metastases are present)

               -  Fasting plasma glucose  &gt; 120mg/dL or &gt; 6.7 mmol/L

               -  HbA1c &gt; 8%.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute SC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meaghan Elliott</last_name>
      <phone>617-632-2166</phone>
      <email>meaghan_elliott@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Y. Wen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center- New York Presbyterian Dept of Oncology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sonia Mendoza</last_name>
      <phone>212-305-9858</phone>
      <email>sm3482@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew B. Lassman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center Duke - Baker</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Carter</last_name>
      <phone>919-668-0896</phone>
      <email>karen.carter@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Annick Desjardins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center SC-3</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiyuan Ni</last_name>
      <phone>713-745-5769</phone>
      <email>jni@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>John F DeGroot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 16, 2014</lastchanged_date>
  <firstreceived_date>June 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>c-MET inhibitor</keyword>
  <keyword>PI3K inhibitor</keyword>
  <keyword>PTEN mutations</keyword>
  <keyword>homozygous deletion of PTEN or PTEN negative by IHC</keyword>
  <keyword>INC280</keyword>
  <keyword>BKM120</keyword>
  <keyword>buparlisib</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
